These findings indicate that despite exhibiting low PD-L1 expression, cancer cells can manifest substantial PD-L1 levels in vivo upon stimulation with T cell-derived IFNγ, consequently circumventing T cell-mediated attacks, which has important implications for selecting immune checkpoint inhibitors. This evidence concerns the gene CD274 and cancer.